Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasms × Biological Products × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Refractory/Relapse Neuroblastoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, B-Cell 1 Kidney Neoplasms 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Paclitaxel 80 Trastuzumab 76 Fulvestrant 53 Cyclophosphamide 49 Capecitabine 42 Lapatinib 40 pembrolizumab 38 Docetaxel 38 palbociclib 35 Carboplatin 32 Letrozole 27 olaparib 23 Doxorubicin 23 Taxes 20 Gemcitabine 20 Everolimus 20 abemaciclib 19 ribociclib 18 Ado-Trastuzumab Emtansine 18 pertuzumab 17 Radiotherapy 17 Magnetic Resonance Spectroscopy 17 Bevacizumab 16 130-nm albumin-bound paclitaxel 16 exemestane 15 Vinorelbine 15 veliparib 14 Cisplatin 14 Biopsy 14 Alpelisib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04382352 2023-03-24

B002-101

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡